ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate UpdateGlobeNewsWire · 3 days ago
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026GlobeNewsWire · 3 days ago
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026GlobeNewsWire · Oct 2, 2026
Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) vs. ProKidney (NASDAQ:PROK)Defense World · Sep 21, 2026
20 stocks likely to lose money even if the bull market continuesMarket Watch · Aug 27, 2026
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)Seeking Alpha · Aug 14, 2026ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.14 | -$0.15 | Miss |
| May 15, 2026 | -$0.13 | -$0.14 | Miss |
| Mar 18, 2026 | -$0.16 | -$0.14 | Beat |
| Nov 10, 2025 | -$0.12 | -$0.12 | Beat |
| Aug 12, 2025 | -$0.14 | -$0.13 | Beat |
| May 12, 2025 | -$0.16 | -$0.13 | Beat |